Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAWN Antivirals Trial for COVID-19
NCT04730206Phase 3Terminated
- Sponsor
- KU Leuven
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of camostat mesilate, molnupiravir in coronavirus disease 2019 (COVID-19), sponsored by KU Leuven. Started Jun 2021; status: terminated.
02
Drugs
camostat mesilatemolnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04730206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730206.